PA
CGEM icon

Profund Advisors’s Cullinan Oncology CGEM Stock Holding History

Profund Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$444K Buy
31,251
+7,969
+34% +$102K 0.02% 595
2025
Q4 		$241K Buy
+23,282
New +$210K 0.01% 1038
2025
Q2 		– Sell
-11,846
Closed -$89.7K – 1001
2025
Q1 		$89.7K Sell
11,846
-5,773
-33% -$55.4K ﹤0.01% 960
2024
Q4 		$215K Sell
17,619
-5,153
-23% -$74.1K 0.01% 973
2024
Q3 		$381K Buy
22,772
+3,420
+18% +$60.7K 0.01% 665
2024
Q2 		$337K Buy
19,352
+4,089
+27% +$87.1K 0.01% 657
2024
Q1 		$260K Buy
+15,263
New +$236K 0.01% 935

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.58B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $369M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return